Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Elizabeth Mary Lamos, Maka Hedrington & Stephen N Davis. (2019) An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors
and SGLT-2 inhibitors. Expert Opinion on Drug Safety 18:8, pages 691-701.
Read now
Read now
André Jacques Scheen. (2018) The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety 17:4, pages 387-405.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
Syed Khalid Imam. (2015) The role of hormonal treatment in type 2 diabetes mellitus. Research and Reports in Endocrine Disorders 5, pages 31-45.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
André J Scheen. (2015) A review of gliptins for 2014. Expert Opinion on Pharmacotherapy 16:1, pages 43-62.
Read now
Read now
Hiroyuki Konya, Yuzo Yano, Satoshi Matsutani, Taku Tsunoda, Takashi Ikawa, Yoshiki Kusunoki, Toshihiro Matsuo, Masayuki Miuchi, Tomoyuki Katsuno, Tomoya Hamaguchi, Jun-ichiro Miyagawa & Mitsuyoshi Namba. (2014) Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Therapeutics and Clinical Risk Management 10, pages 547-558.
Read now
Read now
Articles from other publishers (58)
André J. Scheen. (2023) Clinical pharmacology of antidiabetic drugs: What can be expected of their use?. La Presse Médicale 52:1, pages 104158.
Crossref
Crossref
Jiaman Du, Jiewen Fu, Wenqian Zhang, Lianmei Zhang, Hanchun Chen, Jingliang Cheng, Tao He & Junjiang Fu. (2023)
Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m
6
2
A and CD) regulations on patients with cancer and healthy individuals
. International Journal of Oncology 62:3.
Crossref
Crossref
Elisha Ngetich, Pierfrancesco Lapolla, Anirudh Chandrashekar, Ashok Handa & Regent Lee. (2021) The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review. Vascular Medicine 27:1, pages 77-87.
Crossref
Crossref
Luis D’Marco. 2022. Diabetes and Kidney Disease. Diabetes and Kidney Disease
431
440
.
Hee Seok Jung, Mi Seon Seo, Jin Ryeol An, Ryeon Heo, Minji Kang, Eun-Taek Han, Hongzoo Park, Geehyun Song, Youn Kyoung Son, Won-Kyo Jung, Il-Whan Choi, Sung Hun Na & Won Sun Park. (2021) The anti-diabetic drug alogliptin induces vasorelaxation via activation of Kv channels and SERCA pumps. European Journal of Pharmacology 898, pages 173991.
Crossref
Crossref
Giovanni Cioffi, Carlo Bruno Giorda, Donata Lucci, Elisa Nada, Federica Ognibeni, Costantino Mancusi, Roberto Latini & Aldo P Maggioni. (2021) Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial. European Journal of Preventive Cardiology 28:1, pages 8-17.
Crossref
Crossref
Qi Cheng, Jinluo Cheng, Dennis Cordato & Jianqun Gao. (2020) Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?. Pharmacology & Therapeutics 212, pages 107559.
Crossref
Crossref
Anca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, Dragana Nikolic, Angelo Maria Patti & Ali A. Rizvi. (2020) The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism 109, pages 154295.
Crossref
Crossref
Habib Yaribeygi, Stephen L. Atkin, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2020) A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:3, pages 328-334.
Crossref
Crossref
Carlo Bruno Giorda, Giovanni Cioffi, Donata Lucci, Elisa Nada, Federica Ognibeni, Costantino Mancusi, Roberto Latini & Aldo P. Maggioni. (2019) Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population. Cardiovascular Drugs and Therapy 33:5, pages 547-555.
Crossref
Crossref
Bo Ahrén. (2019) DPP-4 Inhibition and the Path to Clinical Proof. Frontiers in Endocrinology 10.
Crossref
Crossref
Ipseeta Ray Mohanty, Manjusha Borde, Selvaa Kumar C & Ujwala Maheshwari. (2019) Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses. Phytomedicine 57, pages 158-165.
Crossref
Crossref
Amankeldi A. Salybekov, Haruchika Masuda, Kozo Miyazaki, Yin Sheng, Atsuko Sato, Tomoko Shizuno, Yumi Iida, Yoshinori Okada & Takayuki Asahara. (2019) Dipeptidyl dipeptidase-4 inhibitor recovered ischemia through an increase in vasculogenic endothelial progenitor cells and regeneration-associated cells in diet-induced obese mice. PLOS ONE 14:3, pages e0205477.
Crossref
Crossref
Samah S. Abbas, Hesham M. Mahmoud, Mona F. Schaalan & Hanan S. El-Abhar. (2018) Involvement of brain natriuretic peptide signaling pathway in the cardioprotective action of sitagliptin. Pharmacological Reports 70:4, pages 720-729.
Crossref
Crossref
Francisco Carlos Carramiñana Barrera. (2018) Seguridad de los inhibidores de la dipeptidil peptidasa 4. Medicina de Familia. SEMERGEN 44, pages 10-17.
Crossref
Crossref
Peng Men, Xiao-tong Li, Hui-lin Tang & Suo-di Zhai. (2018) Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. PLOS ONE 13:5, pages e0197321.
Crossref
Crossref
André J. Scheen. (2018) Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circulation Research 122:10, pages 1439-1459.
Crossref
Crossref
Rajesh Kumar Suman. (2018) Natural dipeptidyl peptidase-4 inhibitor Terminalia arjuna mitigates myocardial infarction co-existing with diabetes in experimental rats. Journal of Diabetes, Metabolic Disorders & Control 5:2, pages 48-56.
Crossref
Crossref
Michael R. Cobretti, Benjamin Bowman, Ted Grabarczyk & Emily Potter. (2018) Dipeptidyl Peptidase‐4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:3, pages 334-340.
Crossref
Crossref
Phiwayinkosi V. Dludla, Elizabeth Joubert, Christo J.F. Muller, Johan Louw & Rabia Johnson. (2017) Hyperglycemia-induced oxidative stress and heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-O-β-D-glucoside. Nutrition & Metabolism 14:1.
Crossref
Crossref
Mei-Tzu Wang, Sheng-Che Lin, Pei-Ling Tang, Wang-Ting Hung, Chin-Chang Cheng, Jin-Shiou Yang, Hong-Tai Chang, Chun-Peng Liu, Guang-Yuan Mar & Wei-Chun Huang. (2017) The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Raffaella Dell’Oro, Alessandro Maloberti, Francesco Nicoli, Paolo Villa, Pierluigi Gamba, Michele Bombelli, Giuseppe Mancia & Guido Grassi. (2017) Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients. High Blood Pressure & Cardiovascular Prevention 24:4, pages 393-400.
Crossref
Crossref
Shih-Wei Lai, Kuan-Fu Liao, Cheng-Li Lin & Hsien-Feng Lin. (2017) Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study. Frontiers in Pharmacology 8.
Crossref
Crossref
Michael A. NauckJuris J. MeierMatthew A. CavenderMirna Abd El AzizDaniel J. Drucker. (2017) Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation 136:9, pages 849-870.
Crossref
Crossref
André J. Scheen. (2017) Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. Diabetes Research and Clinical Practice 127, pages 224-237.
Crossref
Crossref
Edoardo Mannucci & Matteo Monami. (2016) Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in Therapy 34:1, pages 1-40.
Crossref
Crossref
Andrew J. Krentz. (2016) Hypertension in type 2 diabetes: impact of glucose-lowering medications. Cardiovascular Endocrinology 5:4, pages 137-143.
Crossref
Crossref
Deborah Layton, Abigail L. Coughtrie, Naseer Qayum & Saad A. W. Shakir. (2016) Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription–Event Monitoring Study in England. Drug Safety 39:11, pages 1093-1104.
Crossref
Crossref
Trevor W. R. Lee, Stephen Kowalski, Kelsey Falk, Doug Maguire, Darren H. Freed & Kent T. HayGlass. (2016) High Spinal Anesthesia Enhances Anti-Inflammatory Responses in Patients Undergoing Coronary Artery Bypass Graft Surgery and Aortic Valve Replacement: Randomized Pilot Study. PLOS ONE 11:3, pages e0149942.
Crossref
Crossref
Marcos M. Lima-Martínez, Mariela Paoli, Marianela Rodney, Nathalie Balladares, Miguel Contreras, Luis D’Marco & Gianluca Iacobellis. (2015) Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine 51:3, pages 448-455.
Crossref
Crossref
Yasuko K. Bando & Toyoaki Murohara. (2016) Heart Failure as a Comorbidity of Diabetes: Role of Dipeptidyl Peptidase 4. Journal of Atherosclerosis and Thrombosis 23:2, pages 147-154.
Crossref
Crossref
S. Halimi. (2015) Sécurité cardiovasculaire des incrétines et des inhibiteurs des co-transporteurs sodium-glucose de type 2 (SGLT2). Revue. Médecine des Maladies Métaboliques 9:8, pages 768-775.
Crossref
Crossref
A.J. Scheen, N. Esser & N. Paquot. (2015) Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes & Metabolism 41:3, pages 183-194.
Crossref
Crossref
A.-J. Scheen. (2015) Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique. Médecine des Maladies Métaboliques 9:2, pages 186-197.
Crossref
Crossref
Antoni Sicras-MainarRuth Navarro-Artieda. (2015) Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients. Diabetes & Metabolism Journal 39:1, pages 74.
Crossref
Crossref
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Crossref
Yien Chiong & Carmella Evans-Molina. 2015. PanVascular Medicine. PanVascular Medicine
1541
1593
.
Monica Verdoia, Lucia Barbieri, Alon Schaffer, Ettore Cassetti, Gabriella Di Giovine, Matteo Nardin, Giorgio Bellomo, Paolo Marino & Giuseppe De Luca. (2015) Effect of diabetes mellitus on periprocedural myocardial infarction in patients undergoing coronary stent implantation. Diabetes/Metabolism Research and Reviews 31:1, pages 85-92.
Crossref
Crossref
Erin E. Mulvihill & Daniel J. Drucker. (2014) Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors. Endocrine Reviews 35:6, pages 992-1019.
Crossref
Crossref
Kazufumi Nakamura, Hiroki Oe, Hajime Kihara, Kenei Shimada, Shota Fukuda, Kyoko Watanabe, Tsutomu Takagi, Kei Yunoki, Toru Miyoshi, Kumiko Hirata, Junichi Yoshikawa & Hiroshi Ito. (2014) DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovascular Diabetology 13:1.
Crossref
Crossref
Katia Camarano Nogueira, Meive Furtado, Rosa Tsuneshiro Fukui, Marcia Regina Silva Correia, Rosa Ferreira dos Santos, José Lázaro Andrade & Maria Elizabeth Rossi da Silva. (2014) Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study. Diabetology & Metabolic Syndrome 6:1.
Crossref
Crossref
Lin Yang, Jiao Yuan & Zhiguang Zhou. (2014) Emerging Roles of Dipeptidyl Peptidase 4 Inhibitors: Anti-Inflammatory and Immunomodulatory Effect and Its Application in Diabetes Mellitus. Canadian Journal of Diabetes 38:6, pages 473-479.
Crossref
Crossref
Chris R. Triggle & Hong Ding. (2014) Cardiovascular impact of drugs used in the treatment of diabetes. Therapeutic Advances in Chronic Disease 5:6, pages 245-268.
Crossref
Crossref
Antoni Sicras-MainarRuth Navarro-Artieda. (2014) Healthcare Costs of the Combination of Metformin/Dipeptidyl Peptidase-4 Inhibitors Compared with Metformin/Other Oral Antidiabetes Agents in Patients with Type 2 Diabetes and Metabolic Syndrome. Diabetes Technology & Therapeutics 16:11, pages 722-727.
Crossref
Crossref
Hemant V. Kamble & Subhash L. Bodhankar. (2014) Cardioprotective effect of concomitant administration of trigonelline and sitagliptin on cardiac biomarkers, lipid levels, electrocardiographic and heamodynamic modulation on cardiomyopathy in diabetic Wistar rats. Biomedicine & Aging Pathology 4:4, pages 335-342.
Crossref
Crossref
Leila Ganjehei, Urmiya Mamoon Rashid, Sara Payami & Andrew Kim Saal. (2014) ST elevation myocardial infarction: recent advances and updates. Future Cardiology 10:5, pages 633-666.
Crossref
Crossref
Guntram Schernthaner & Naveed Sattar. (2014) Lessons from SAVOR and EXAMINE: Some important answers, but many open questions. Journal of Diabetes and its Complications 28:4, pages 430-433.
Crossref
Crossref
Gillian M. Keating. (2014) Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 74:5, pages 587-610.
Crossref
Crossref
Angela Dardano, Giuseppe Penno, Stefano Del Prato & Roberto Miccoli. (2014) Optimal therapy of type 2 diabetes: a controversial challenge. Aging 6:3, pages 187-206.
Crossref
Crossref
A. Hormigo Pozo & J. Mancera Romero. (2014) Seguridad cardiovascular de los nuevos fármacos para la diabetes tipo 2. SEMERGEN - Medicina de Familia 40:2, pages 55-56.
Crossref
Crossref
Claudio D’Amore, Francesco Saverio Di Leva, Valentina Sepe, Barbara Renga, Chiara Del Gaudio, Maria Valeria D’Auria, Angela Zampella, Stefano Fiorucci & Vittorio Limongelli. (2014) Design, Synthesis, and Biological Evaluation of Potent Dual Agonists of Nuclear and Membrane Bile Acid Receptors. Journal of Medicinal Chemistry 57:3, pages 937-954.
Crossref
Crossref
M. Krempf. (2014) Étude de la saxagliptine sur la survenue d’événements cardiovasculaires chez des patients diabétiques de type 2 (Étude SAVOR-TIMI 53) : les résultats. Médecine des Maladies Métaboliques 8:1, pages 61-64.
Crossref
Crossref
Greg L. Plosker. (2014) Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:2, pages 223-242.
Crossref
Crossref
Sandeep Dhindsa & Ishwarlal Jialal. (2014) Potential Anti-Atherosclerotic Effects of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus. Current Diabetes Reports 14:2.
Crossref
Crossref
Yien Chiong & Carmella Evans-Molina. 2013. PanVascular Medicine. PanVascular Medicine
1
65
.
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2015) The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2015) Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2013) Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Crossref